People: OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

22.09USD
4:00pm EDT
Price Change (% chg)

$0.98 (+4.64%)
Prev Close
$21.11
Open
$21.12
Day's High
$22.48
Day's Low
$20.81
Volume
32,820
Avg. Vol
43,310
52-wk High
$42.34
52-wk Low
$12.10

Search Stocks

Summary

Name Age Since Current Position

James Woody

Chairman of the Board

Paul Hastings

54 President, Chief Executive Officer and Board Member

Sunil Patel

42 2014 Chief Financial Officer, Senior Vice President - Corporate Development and Finance

John Lewicki

54 Executive Vice President, Chief Scientific Officer

Jakob Dupont

Senior Vice President and Chief Medical Officer

Michael Wyzga

59 2013 Independent Director

Biographies

Name Description

James Woody

Dr. James N. Woody, M.D., Ph.D. is the Chairman of the Board of OncoMed Pharmaceuticals, Inc. He also is the General Partner of Latterell Venture Partners. He brings more than 25 years of pharmaceutical research and management experience. He previously served as the founding Chief Executive Officer of OncoMed Pharmaceuticals, Inc. He was formerly President of Roche Bioscience. Previously, he served as Chief Scientific Officer and Senior Vice President of Research and Development for Centocor. Prior to Centocor, he served as Commanding Officer and Director of United States Naval Medical Research and Development Command in Bethesda Maryland. He holds a M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Childrens Hospital in Boston (Harvard), and holds a Doctor of Philosophy in Immunology from the University of London, England.

Paul Hastings

Mr. Paul J. Hastings is the President, Chief Executive Officer and Board Member at OncoMed Pharmaceuticals, Inc. He brings more than 20 years of experience as a biotechnology and pharmaceutical industry executive. He has served as President and Chief Executive Officer of OncoMed Pharmaceuticals since January 2006. Prior to joining OncoMed, he was President and Chief Executive Officer of QLT, Inc. He served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President of Worldwide Therapeutics. He also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. He was Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2009), and served on the boards of ViaCell (sold to Perkin-Elmer in 2008), and Cerimon Pharmaceuticals. He holds a Bachelor of Science in Pharmacy from the University of Rhode Island.

Sunil Patel

Mr. Sunil Patel has been appointed as Chief Financial Officer, Senior Vice President - Corporate Development and Finance of the Company, effective as of March 31, 2014. Mr. Patel has served as our Senior Vice President, Chief Business Officer since December 2012 and previously served as our Senior Vice President, Corporate Development since July 2009. From September 2008 to June 2009, Mr. Patel served as the Vice President of Corporate Development & Marketing at BiPar Sciences Inc., a privately-held biotechnology company that focused on the development of cancer therapies and was acquired by Sanofi-Aventis S.A. in 2009. From May 2007 to August 2008, Mr. Patel served as the Vice President of Corporate Development at Allos Therapeutics, Inc., a publicly-traded biopharmaceutical company focused on the development and commercialization of cancer therapeutics. Prior to that time, Mr. Patel held corporate development, marketing, and strategy positions with Connetics Corporation, Abgenix, Inc. and Gilead Sciences, Inc. Mr. Patel also previously worked as a consultant with McKinsey & Company from 1998 to 2003. Since October 2010, Mr. Patel has served on the board of directors of Ligand Pharmaceuticals, Inc., a publicly-traded biotechnology company. Mr. Patel received a B.S. in Chemistry from the University of California Berkeley and an M.S. in Molecular Bioengineering/Biotechnology from the University of Washington.

John Lewicki

Dr. John Lewicki, Ph.D., is the Executive Vice President and Chief Scientific Officer at OncoMed Pharmaceuticals, Inc. He joined OncoMed after serving 16 years with Scios, Inc. He has been Senior Vice President of Research and Development of an early-stage biotechnology company working in the infectious disease field. He holds a Ph.D in Physiology/Pharmacology from University of California, San Diego and conducted his post-doctoral training at University of Virginia and Stanford University.

Jakob Dupont

Dr. Jakob Dupont, M.D. is the Senior Vice President and Chief Medical Officer of OncoMed Pharmaceuticals, Inc. He is a medical Oncologist with academic and pharmaceutical oncology drug development experience. He joined OncoMed from Genentech, where he was Global Medical Director for Avastin (bevacizumab). While at Genentech, Dr. Dupont held leadership positions at all stages of oncology drug development from Phase 1 through Phase IV. Prior to this, he held development leadership positions on the Avastin franchise for the Breast Cancer and the Ovarian Cancer indications. He also held leadership position in the Exploratory Clinical Development group. Prior to his work with industry, he held a faculty appointment at Memorial Sloan-Kettering Cancer Center. He holds a M.D. from Weill Medical College of Cornell and completed his Internal Medicine training at the University of Michigan and the New York-Presbyterian Hospital. He went on to complete his medical oncology training at Memorial Sloan-Kettering Cancer Center. He continues to care for gynecologic oncology patients and teach as an Adjunct Clinical Assistant Professor at Stanford University Medical Center.

Michael Wyzga

Mr. Michael S. Wyzga is Independent Director of OncoMed Pharmaceuticals, Inc. Mr. Wyzga is currently President and Chief Executive Officer of Radius Health, Inc. Prior to joining Radius, Mr. Wyzga was Executive Vice President, Finance and Chief Financial Officer of Genzyme Corporation until its acquisition by Sanofi in April 2011. Mr. Wyzga joined Genzyme in 1998 and held primary responsibility for the company’s financial management worldwide. He provided key leadership in the successful $20.1 billion sale of Genzyme to Sanofi, which was the second-largest acquisition in biotechnology history. Prior to joining Genzyme, Mr. Wyzga was Chief Financial Officer of Sovereign Hill Software. He previously served as Vice President of Finance and Chief Financial Officer of CacheLink Corporation, a client/service software company. Mr. Wyzga also held management positions at Lotus Development Corporation and Digital Equipment Corporation. He received an MBA from Providence College and a BS from Suffolk University.

Basic Compensation

Name Fiscal Year Total

James Woody

--

Paul Hastings

--

Sunil Patel

--

John Lewicki

--

Jakob Dupont

--

Michael Wyzga

--
As Of 

Options Compensation

Search Stocks